Dr. Matthias Magoola, the founder and chief executive officer of Dei Group of Companies, has been recognized for his entrepreneurship.
The recognition and subsequent award took place during the 10th International Excellence and Global Leadership Award by the Fame Times International Excellence Awards in Bangkok, Thailand, recently.
According to the award testimonial, Magoola is creating thousands of professional jobs, in addition to being an advanced therapeutics researcher and innovator.
In recognition of his outstanding professional and humanity-empowering milestones, Magoola was awarded a professional doctorate in management by the European International University of France at the same event.
Magoola is establishing a facility to manufacture mRNA, gene therapy, and other novel biological therapies.
The project is being set up in Matugga, Wakiso District, at a total cost of $1.1 billion (approximately 4.3 trillion Ugandan shillings).
A trained biochemist, Magoola has led the Dei Group over the years, creating a portfolio of sub-companies across diverse sectors. His most significant current development is the biological drugs and vaccines manufacturing facility in Matugga, Wakiso District, spearheaded by Dei Biopharma Ltd.
Magoola, recognized for innovative discoveries in advanced therapies, described his doctorate and publications as critical milestones in the fight against several incurable diseases, including neurodegenerative disorders, HIV/AIDS, HPV, and cancers.
He has been acknowledged for his visionary success and groundbreaking achievements in advanced therapies, including:
- The first US-patented chemical drug using N-Isobutyll-3, 4-metheylenedioxy-trans-cinnamide compositions to treat malaria.
- The first mRNA universal vaccine against malaria.
- Other mRNA vaccines targeting neurodegenerative disorders, diabetes, HIV, and HPV.
- The mRNA-based vaccine composition for inducing an immune response against HIV and HPV, patented under certificate number 63921929 in the USA.
- Ten additional patents for treatments of previously untreatable diseases, all registered in the United States.
Contributions to Scientific Research
Beyond his scientific innovations, Magoola actively contributes to scientific journals, sharing his findings through peer-reviewed publications. A few examples of his published research include:
- “Synergistic Approaches in Neurodegenerative Therapeutics: Multi-Target Drug Innovative Interventions for Alzheimer’s Disease”
- “Advances in Escherichia coli-Based Therapeutic Protein Expression: Mammalian Conversion, Continuous Manufacturing, and Cell-Free Production”
- “mRNA and Synthesis-Based Therapeutic Proteins: A Non-Recombinant Affordable Option”
Magoola described his doctorate and publications as critical milestones in addressing some of the world’s most challenging diseases.
“We have found the most innovative new ways to treat neurodegenerative disorders for the first time,” he said.
He also emphasized that his publications and innovative discoveries are elevating the global reputation of Ugandan researchers in the field of science.
Appreciation for Presidential Support
Magoola expressed gratitude to President Yoweri Museveni for his unwavering support for Ugandan scientists, particularly for backing the Dei Biopharma drugs and vaccines manufacturing project.
“Without his dedicated support, we would not be achieving these milestones, and it is fair that we must thank and credit him for these achievements,” Magoola said.
SOURCE: NEWVISION WEBSITE
